Generali Investments Towarzystwo Funduszy Inwestycyjnych Crispr Therapeutics Ag Transaction History
Generali Investments Towarzystwo Funduszy Inwestycyjnych
- $192 Billion
- Q2 2025
A detailed history of Generali Investments Towarzystwo Funduszy Inwestycyjnych transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Generali Investments Towarzystwo Funduszy Inwestycyjnych holds 21,000 shares of CRSP stock, worth $1.52 Million. This represents 0.53% of its overall portfolio holdings.
Number of Shares
21,000
Previous 21,000
-0.0%
Holding current value
$1.52 Million
Previous $715 Million
42.93%
% of portfolio
0.53%
Previous 0.45%
Shares
6 transactions
Others Institutions Holding CRSP
# of Institutions
543Shares Held
68.7MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$736 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$405 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$266 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$237 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$206 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $5.64B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....